Picture of Theravance Biopharma logo

TBPH Theravance Biopharma News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Theravance Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

* Theravance Biopharma Inc  TBPH.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -17 cents.  The mean expectation of four analysts for the
quarter was for a loss of 23 cents per share. Wall Street
expected results to range from -28 cents to -19 cents per share.
    * Revenue rose 7.5% to $16.87 million from a year ago;
analysts
expected $15.34 million. 
    * Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 26 cents​.
    * The company reported a quarterly loss of $12.7 million.
    * Theravance Biopharma Inc shares had risen by 12.7% this
quarter and lost 19.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Theravance
Biopharma Inc is $11.00 
This summary was machine generated from LSEG data November 13 at
12:08 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.23          -0.26          Missed
 Jun. 30 2024      -0.21          -0.28          Missed
 Mar. 31 2024      -0.25          -0.24          Beat
 Dec. 31 2023      -0.15          -0.17          Missed

Recent news on Theravance Biopharma

See all news